Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-02-03
DOI
10.3389/fonc.2020.608772
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor Immunology and Tumor Evolution: Intertwined Histories
- (2020) Jérôme Galon et al. IMMUNITY
- Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
- (2020) Matthias Guckenberger et al. LANCET ONCOLOGY
- NK cells for cancer immunotherapy
- (2020) Noriko Shimasaki et al. NATURE REVIEWS DRUG DISCOVERY
- B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade
- (2020) Sangwoo S. Kim et al. CLINICAL CANCER RESEARCH
- Oligometastatic head and neck cancer: Comprehensive review
- (2020) Toms Vengaloor Thomas et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Progression-free survival, overall survival and immunophenotyping outcomes for patients with stage III-IV head and neck cancer and cisplatin contraindication treated with definitive radiotherapy plus pembrolizumab
- (2020) J. Weiss et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study
- (2020) Steven F. Powell et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
- (2020) Ryan Phillips et al. JAMA Oncology
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
- (2020) Lorenzo Galluzzi et al. Journal for ImmunoTherapy of Cancer
- Keynote 48: Is it really for everyone?
- (2020) Jonathan D. Schoenfeld et al. ORAL ONCOLOGY
- Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
- (2020) Sean McBride et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma
- (2020) Jonathan D. Schoenfeld et al. JAMA Oncology
- Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy
- (2019) Aurelie Hanoteau et al. Journal for ImmunoTherapy of Cancer
- ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment
- (2019) Magnus T. Dillon et al. CLINICAL CANCER RESEARCH
- Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
- (2019) David A Palma et al. LANCET
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features
- (2019) Jonathan D. Schoenfeld et al. Journal for ImmunoTherapy of Cancer
- Immune evasion before tumour invasion in early lung squamous carcinogenesis
- (2019) Céline Mascaux et al. NATURE
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
- (2019) Willemijn S. M. E. Theelen et al. JAMA Oncology
- Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
- (2019) Nicholas D. Klemen et al. Journal for ImmunoTherapy of Cancer
- Radiotherapy with Concurrent and Adjuvant Pembrolizumab in Patients with P16-Positive Locoregionally Advanced Head and Neck Cancer: KEYCHAIN Trial Lead-In Results
- (2019) A.G. Sacco et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Integration of radiotherapy and immunotherapy for treatment of oligometastases
- (2019) Sean P Pitroda et al. LANCET ONCOLOGY
- Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial
- (2019) Joris B.W. Elbers et al. RADIOTHERAPY AND ONCOLOGY
- Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition
- (2019) Jared M. Newton et al. Journal for ImmunoTherapy of Cancer
- 1192OAssociation of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158
- (2019) A Marabelle et al. ANNALS OF ONCOLOGY
- Patterns of Disease Progression with Durvalumab in Stage III Non-small Cell Lung Cancer (PACIFIC)
- (2019) D. Raben et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Tumor-reprogrammed resident T cells resist radiation to control tumors
- (2019) Ainhoa Arina et al. Nature Communications
- HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma
- (2019) Jian Wang et al. Scientific Reports
- Enhanced Radiation Sensitivity of Human Papillomavirus-Driven Head and Neck Cancer: Focus on Immunological Aspects
- (2019) Mine Özcan-Wahlbrink et al. Frontiers in Immunology
- Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma
- (2018) Jonathan D. Schoenfeld et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
- (2018) Jason J. Luke et al. JOURNAL OF CLINICAL ONCOLOGY
- Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
- (2018) Piet Ost et al. JOURNAL OF CLINICAL ONCOLOGY
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Safety of combining radiotherapy with immune-checkpoint inhibition
- (2018) William L. Hwang et al. Nature Reviews Clinical Oncology
- Hazards of Hazard Ratios — Deviations from Model Assumptions in Immunotherapy
- (2018) Brian M. Alexander et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer
- (2018) Roy Xiao et al. OncoImmunology
- Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation
- (2018) Allison M. Martin et al. JAMA Oncology
- Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer
- (2018) Puneeth Iyengar et al. JAMA Oncology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The impact of radiation therapy on lymphocyte count and survival in metastatic cancer patients receiving PD-1 immune checkpoint inhibitors
- (2018) Luke R.G. Pike et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Preliminary toxicity data from the combination of pembrolizumab and definitive-dose radiotherapy for locally advanced head and neck cancer with contraindication to cisplatin therapy.
- (2018) Jared Weiss et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504.
- (2018) Robert L. Ferris et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.
- (2018) Xu Shan Sun et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH).
- (2018) Yungan Tao et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy
- (2018) Y -P Chen et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
- (2018) Zachary S. Buchwald et al. Frontiers in Oncology
- Immunotherapy and radiotherapy for metastatic cancers
- (2018) Andrew Bang et al. Annals of Palliative Medicine
- Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy
- (2017) Andrew Bang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- SBRT for oligoprogressive oncogene addicted NSCLC
- (2017) L. Basler et al. LUNG CANCER
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Radiotherapy and immunotherapy: a beneficial liaison?
- (2017) Ralph R. Weichselbaum et al. Nature Reviews Clinical Oncology
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer
- (2017) Megan Morisada et al. ORAL ONCOLOGY
- Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation
- (2017) Luke R.G. Pike et al. RADIOTHERAPY AND ONCOLOGY
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma
- (2017) Ayman Oweida et al. OncoImmunology
- PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation
- (2017) Megan Morisada et al. OncoImmunology
- Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques
- (2017) Jonathan E. Leeman et al. JAMA Oncology
- Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx
- (2016) Ankur Chakravarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?
- (2016) Rovel J. Colaco et al. JOURNAL OF NEUROSURGERY
- Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
- (2016) Daniel R Gomez et al. LANCET ONCOLOGY
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant
- (2015) Kobe Reynders et al. CANCER TREATMENT REVIEWS
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
- (2015) Jeffrey D Bradley et al. LANCET ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
- (2014) Liufu Deng et al. IMMUNITY
- Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
- (2014) A. B. Sharabi et al. Cancer Immunology Research
- Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
- (2014) Encouse B Golden et al. OncoImmunology
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Response During Therapy With Cisplatin or Radiation for Human Papillomavirus–Related Head and Neck Cancer
- (2009) William C. Spanos et al. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now